Date: 2016-06-02
Type of information: Financing round
Company: LSP (Life Sciences Partners) (The Netherlands)
Investors:
Amount: $280 million (€250,2 million)
Funding type: financing round
Planned used: The new life sciences fund LSP 5 targets investment opportunities in healthcare companies developing pioneering products and technologies that provide solutions to unmet medical needs, similar to its predecessor funds. The fund has already started to invest, taking positions in 9 companies. Examples include Irish medical device company Neuravi, active in acute ischemic stroke, Swiss-based immuno-oncology company Nouscom, and Kuros Biosciences, recently listed on the Swiss Stock Exchange and focused on tissue repair and regeneration. The fund, primarily focused on Europe, will look to invest in around 20 companies across the areas of drug development, medical devices and diagnostics.
Others: * On June 2, 2016, LSP (Life Sciences Partners), the European life sciences investment group, announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target and reached the ‘hard cap’ of $280 million, making LSP 5 one of the largest life sciences funds in Europe.
Therapeutic area:
